title: Effects of the immunomodulator LS 2616 on lymphocyte subpopulations in murine Coxsackievirus B3 myocarditis.
abstract: Quinoline-3-carboxamide (LS 2616) is a broadly acting immunostimulator with anti-inflammatory effects in Coxsackie virus B3-induced myocarditis in female BALB/c mice. This infection caused extensive inflammatory and necrotic lesions in the myocardium 7 days after inoculation (6.8% of tissue section area). The damaged area was reduced (to 3.7% (p less than 0.05] and the lethality decreased when LS 2616 was administered over 14 days, starting 7 days before the inoculation. The response pattern of lymphocyte subsets in situ in myocardial inflammatory lesions was elucidated by a newly developed immune histochemical staining technique. LS 2616 increased the number of class II-expressing cells 3-fold (p less than 0.01) and the CTL, Ts:Th cell ratio by 55% (p less than 0.05), whereas Lyt-1+ and TIB+ cells were unaffected. After 7 days of LS 2616 treatment, spleen lymphocyte activity tended to increase (T cells by 21% (NS) and B cells by 60% (p less than 0.05), respectively). The activity of NK cells increased by 51% (p less than 0.01). LS 2616 may thus have potential in therapy of human inflammatory disorders, such as myocarditis.
authors.affiliation: Toxicology Laboratory, Swedish National Food Administration, Uppsala.
authors.forename: N G
authors.initials: NG
authors.lastname: Ilbäck
authors.forename: J
authors.initials: J
authors.lastname: Fohlman
authors.forename: S
authors.initials: S
authors.lastname: Slorach
authors.forename: G
authors.initials: G
authors.lastname: Friman
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D003384:Coxsackievirus Infections / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D029822:Enterovirus B, Human; D005260:Female; D006912:Hydroxyquinolines / Q000008:administration & dosage*; D008214:Lymphocytes / Q000145:classification / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D009205:Myocarditis / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D011292:Premedication; D013154:Spleen / Q000187:drug effects; D013950:Thymus Gland / Q000187:drug effects
chemical_list: D000276:Adjuvants, Immunologic; D006912:Hydroxyquinolines; C045282:roquinimex